Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma

Mayo Clinic Proceedings

Volumn 78, Issue 1, 2003, Pages 34-39

  Kumar, Shaji ^a   Gertz, Morie A ^a   Dispenzieri, Angela ^a   Lacy, Martha Q ^a   Geyer, Susan M ^a   Iturria, Nancy L ^a   Fonseca, Rafael ^a   Hayman, Suzanne R ^a   Lust, John A ^a   Kyle, Robert A ^a   Greipp, Philip R ^a   Witzig, Thomas E ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; THALIDOMIDE;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MORTALITY; MULTIPLE MYELOMA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; RASH; RELAPSE; SEDATION; SIDE EFFECT; SINUS BRADYCARDIA; STEM CELL TRANSPLANTATION; SURVIVAL; SURVIVAL TIME; THROMBOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VERTIGO;

EID: 0037216068     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/78.1.34     Document Type: Article

References (37)

1. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR, Mayo Clinic Myeloma, Amyloid, and Dysproteinemia Group. Current therapy for multiple myeloma. Mayo Clin Proc. 2002;77:813-822.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002 [published corrections appear in CA Cancer J Clin. 2002;52:119, 2002;52:181-182]. CA Cancer J Clin. 2002;52:23-47.
3. Kyle RA. Long-term survival in multiple myeloma. N Engl J Med. 1983;308:314-316.
4. Attal M, Harousseau JL, Stoppa AM, et al, Intergroupe Francais du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
5. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87: 503-508.
6. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000; 6:3111-3116.
7. Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002;8:2210-2216.
8. Sezer O, Niemoller K, Eucker J, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol. 2000;79:574-577.
9. Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol. 2001;28:565-569.
10. Anderson KC. Multiple myeloma: Advances in disease biology: Therapeutic implications. Semin Hematol. 2001;38(2, suppl 3):6-10.
11. Rajkumar SV, Kyle RA. Angiogenesis in multiple myeloma. Semin Oncol. 2001;28:560-564.
12. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [published correction appears in N Engl J Med. 2000;342:364]. N Engl J Med. 1999;341:1565- 1571.
13. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91: 4082-4085.
14. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al, Polish Multiple Myeloma Study Group. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica. 2001;86:404-408.
15. Grosbois B, Bellissant E, Moreau P, Attal M, Zerbib R, Intergroupe Francophone du Myélome. Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM): A prospective study of 120 patients [abstract]. Blood. 2001;98(pt 1):163a. Abstract 689.
16. Barlogie B, Spencer T, Tricot G, et al. Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM) [abstract]. Blood. 2000;96(pt 1):514a. Abstract 2213.
17. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc. 2000; 75:897-901.
18. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492-494.
19. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998; 16:3832-3842.
20. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.
21. Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15:1274-1276.
22. Tosi P, Ronconi S, Zamagni E, et al. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Haematologica. 2001;86: 409-413.
23. Tosi P, Zamagni E, Cellini C, et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica. 2002;87:408-414.
24. Neben K, Moehler T, Kraemer A, et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol. 2001;115:605-608.
25. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675-1680.
26. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943-2950.
27. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998;187:1885-1892.
28. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Thl cytokine production in mitogen- and antigenstimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol. 1995;99:160-167.
29. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade, Immunopharmacology. 1996;31:213-221.
30. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001;276:22382-22387.
31. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
32. Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica. 2001;86:399-403.
33. Ahmad I, Islam T, Chanan-Khan A, et al. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Bone Marrow Transplant. 2002;29:577-580.
34. Rajkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma [letter]. N Engl J Med. 2000;343:972-973.
35. Camba L, Peccatori J, Pescarollo A, Tresoldi M, Corradini P, Bregni M. Thalidomide and thrombosis in patients with multiple myeloma [letter]. Haematologica. 2001;86:1108-1109.
36. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deepvein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-1615.
37. Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma [letter]. N Engl J Med. 2001;344:1951-1952.